title: [Clinical study of COAD-B regimen in treatment of patients with relapsed/refractory non-Hodgkin lymphoma].
abstract: OBJECTIVE
  To investigate the efficacy, adverse events and long-term survival of cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin (COAD-B) regimen for relapsed and refractory non-Hodgkin lymphoma (NHL).
  
  
  METHODS
  Eighty six patients diagnosed with relapsed or refractory NHL were included in our study from January 2007 to January 2013. The chemotherapy regimen was COAD-B, the therapeutic efficacy was evaluated every 2 courses. Once the stable disease (SD) or progress of the disease (PD) achieved, the patients would switch to other second-line regimens.
  
  
  RESULTS
  The overall response rate (ORR) was 67.4%, median remission duration was 13 months (3-51 months); 1-,2- and 4-year overall survival (OS) rates were 75.4%, 56.8% and 40.0%, respectively; 1-, 2- and 4-year progression-free survival (PFS) rates were 50.3%, 39.4% and 27.5%, respectively. The main adverse reaction of patients was myelosuppression. The response to chemotherapy and long- term survival of the relapsed patients were significantly better than that of the refractory ones, and the difference had statistical significance.
  
  
  CONCLUSIONS
  COAD-B could be the salvage regimen for relapsed and refractory NHL.
authors.affiliation: Department of Hematopathy, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
authors.forename: Ming-hui
authors.initials: MH
authors.lastname: Li
authors.forename: Yu-fu
authors.initials: YF
authors.lastname: Li
authors.forename: Qing-song
authors.initials: QS
authors.lastname: Yin
authors.forename: Rui-hua
authors.initials: RH
authors.lastname: Mi
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.forename: Jian-wei
authors.initials: JW
authors.lastname: Du
authors.forename: Xu-dong
authors.initials: XD
authors.lastname: Wei
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D018572:Disease-Free Survival; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D003907:Dexamethasone; D003520:Cyclophosphamide; D014751:Vindesine